Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Fibrosis is present in an important proportion of myocardial disorders. Injury activates cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness, impairing cardiac function, and leading to heart failure. Clinical therapies that directly target excessive fibrosis a...

Full description

Bibliographic Details
Main Authors: Gemma Ferrer-Curriu, Carolina Soler-Botija, Sandra Charvatova, Benjamin Motais, Santiago Roura, Carolina Galvez-Monton, Marta Monguió-Tortajada, Oriol Iborra-Egea, Michele Emdin, Josep Lupón, Alberto Aimo, Juli R. Bagó, Antoni Bayés Genís
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Cardiac fibrosis
Immunotherapy
CAR T
Natural killer cells
CAR NK
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222014500

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222014500

Similar Items